Updates on the The Role of Adjuvant Therapy in NSCLC
ESMO 2022 Updated Results From ADAURA: Osimertinib as Adjuvant Therapy in Patients With Resected EGFRm Stage IB–IIIA NSCLC
By
ESMO 2022 Conference Coverage
FEATURING
Tom John
By
ESMO 2022 Conference Coverage
FEATURING
Tom John
Login to view comments.
Click here to Login
Updates on the The Role of Adjuvant Therapy in NSCLC